ATYR

aTyr Pharma
ATYR
Market cap $281M

3.35 USD

+0.20

6.35%

At close Dec 20, 4:00 PM EST

After hours

3.39

+0.04

1.19%

1 day

6.35%

5 days

9.12%

1 month

12.04%

3 months

84.07%

6 months

112.03%

Year to date

123.33%

1 year

155.73%

5 years

-20.05%

10 years

-98.40%

About: aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Employees: 59

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,809 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

960% more call options, than puts

Call options by funds: $53K | Put options by funds: $5K

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

17% more funds holding

Funds holding: 47 [Q2] → 55 (+8) [Q3]

15% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 13

6% more capital invested

Capital invested by funds: $79.8M [Q2] → $84.2M (+$4.42M) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

10.95% less ownership

Funds ownership: 74.08% [Q2] → 63.13% (-10.95%) [Q3]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$17

407%

upside

Avg. target

$26

676%

upside

High target

$35

945%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 80 / 385 met price target	945%upside $35	Buy Reiterated	10 Dec 2024
Wells Fargo Derek Archila 53% 1-year accuracy 19 / 36 met price target	407%upside $17	Overweight Initiated	4 Oct 2024

See Analyst Rankings

Financial journalist opinion

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company's Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. (Neurocrine).

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present two posters related to its tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution, which is scheduled to take place December 8 – 11, 2024, in Whistler, British Columbia, Canada. Details of the presentations appear below.

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

aTyr Pharma: The Bull Has Finally Come Out

aTyr Pharma has a pivotal year ahead with key readouts for Efzofitimod in pulmonary sarcoidosis and SSC-ILD, potentially opening a huge market. Efzofitimod aims to modulate inflammation without immune suppression, setting it apart from traditional treatments, with promising post-hoc results in higher doses. aTyr is well-funded with $81 million in cash, sufficient for upcoming trial readouts, and has seen significant stock performance and insider buying.

aTyr Pharma: The Bull Has Finally Come Out

aTyr Pharma to Present at the LD Micro Main Event XVII in October

San Diego, California--(Newsfile Corp. - October 14, 2024) - aTyr Pharma, Inc. (NASDAQ: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D.

aTyr Pharma to Present at the LD Micro Main Event XVII in October

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

Topline data from phase 3 EFZO-FIT study, using efzofitimod for the treatment of patients with pulmonary sarcoidosis, expected Q3 of 2025. The 7 major pulmonary sarcoidosis markets are expected to reach a value of $53.3 billion by 2034. Topline data from the phase 2 EFZO-CONNECT study, using efzofitimod for the treatment of patients with scleroderma-related ILD, expected Q2 of 2025.

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

aTyr Pharma to Participate in September Investor Conferences

SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in several upcoming investor conferences scheduled to take place in September 2024. Details of the conferences appear below: Conference: Wells Fargo Healthcare ConferenceDate: Thursday, September 5, 2024 Location: Everett, MAFormat: 1x1 Investor Meetings Conference: H.C.

aTyr Pharma to Participate in September Investor Conferences

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025. Ended the second quarter 2024 with $81.4 million in cash, cash equivalents, restricted cash and investments.

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

Zacks Investment Research

Is aTyr Pharma (ATYR) Outperforming Other Medical Stocks This Year?

Here is how Atyr Pharma (ATYR) and High Tide Inc. (HITI) have performed compared to their sector so far this year.

Is aTyr Pharma (ATYR) Outperforming Other Medical Stocks This Year?

See News Rankings

Charts implemented using Lightweight Charts™